Ipsen SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ipsen SA announces positive top line results from phase III clinical study of Decapeptyl
Ipsen SA:Announced that the phase III clinical trial evaluating Decapeptyl 11.25 mg administered subcutaneously in patients with locally advanced or metastatic prostate cancer has met its primary endpoints.Based on these results, Ipsen intends to apply for the addition of the subcutaneous route, alongside the intramuscular route, to the label of triptorelin pamoate 11.25 mg.
Latest Developments for Ipsen SA
- Ipsen SA announces new drug application submitted to U.S. Food And Drug Administration
- Ipsen SA announces first set of results on positive phase III clinical study of Dysport in treatment of adults suffering from Upper Limb Spasticity
- Ipsen SA announces positive results from phase IIa clinical study of Dysport in treatment of patients with Neurogenic Detrusor Overactivity (NDO)
- Ipsen SA announces clinical results of Dysport Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW
- Share this
- Digg this